We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
As drug prices climb and the Trump administration works over ways to lower them, FDA commissioner Scott Gottlieb, M.D., has homed in on insulin prices as his agency's next target.